CPT2 and metabolic dysfunction-associated steatohepatitis: It has been reported that, in patients with nonalcoholic steatohepatitis (NASH), lipotoxicity for hepatocellular carcinoma (HCC) cells is thwarted by CPT2 downregulation-mediated suppression of FAO.